Intuitive Surgical, Inc. (ISRG.US) reported a strong 23% increase in revenue in Q3, with a subsequent 17% surge in after-hours trading. The growth was driven by a significant increase in Da Vinci surgical procedures.

On the evening of October 21st (Tuesday) Eastern Time, Intuitive Surgical, Inc., the global technology leader in the minimally invasive care field, and the pioneer in assisted surgery, Siasun Robot & Automation, released their financial performance for the quarter ending September 30, 2025. The financial report showed that the company's third-quarter revenue reached $25.1 billion, a 23% increase from $20.4 billion in the third quarter of 2024; on a GAAP basis, net profit was $704 million, diluted earnings per share were $1.95, compared to $565 million and $1.56 in the same period last year; non-GAAP net profit was $867 million, with diluted earnings per share of $2.40, compared to $669 million and $1.84 in the prior year period. It is reported that the revenue growth was mainly driven by an increase in the number of surgeries, deployment of Da Vinci surgical systems, and expansion of equipment installation. During this quarter, the company deployed 427 Da Vinci systems, a significant increase from 379 in the same period last year; 50 Ion systems were deployed, compared to 58 in the previous year. The number of surgeries increased by approximately 20% year-on-year, with Da Vinci system surgeries increasing by about 19% and Ion system surgeries increasing by about 52%. As of the end of the third quarter of 2025, the company's total cash, cash equivalents, and investments amounted to $8.43 billion, a decrease of $1.1 billion from the beginning of the quarter, compared to approximately $8.8 billion on December 31, 2024. The decrease was primarily due to cash used for stock repurchases and capital expenditures, partially offset by operating cash flow. In addition, the company repurchased 4 million shares of stock for $1.92 billion. Looking ahead, the company expects global Da Vinci surgical system surgery volume growth of approximately 17% to 17.5% for the full year of 2025, compared to 17% in 2024; non-GAAP gross margin is expected to be between 67% and 67.5% of revenue, compared to 69.1% in 2024, with this range including approximately 0.7% of revenue impact from tariffs (fluctuating by 10 basis points); non-GAAP operating expense growth is expected to be 11% to 13%, compared to 10% in 2024. As of the time of this release, Intuitive Surgical, Inc. rose over 17% in after-hours trading to $543.00.